Eben Tessari compensation by year
Kiniksa Pharmaceuticals International Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $586,460 |
| Bonus | $1,084,019 |
| Stock awards | $1,084,019 |
| Option awards | $533,278 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $5,865 |
| Total | $3,566,231 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kiniksa Pharmaceuticals International, plc DEF 14A filed April 16, 2026, accession 0001104659-26-044410, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 19,657 | $810,851 | — |
| RSU | 9,828 | $405,405 | — |
| PSU | 5,585 | $230,381 | — |
| RSU | 5,235 | $215,944 | — |
| PSU | 5,224 | $215,490 | — |
| PSU | 4,975 | $205,219 | — |
| RSU | 3,545 | $146,231 | — |
| RSU | 2,726 | $112,448 | — |
| Option | 14,181 | — | $10.76 |
| Option | 5,451 | — | $11.10 |
| Option | 12,266 | — | $11.97 |
| Option | 24,956 | — | $26.74 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Kiniksa Pharmaceuticals International, plc's FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 16 award rows shown.
Kiniksa Pharmaceuticals International’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sanj Patel | Chief Executive Officer and Chairman of the Board | $10,782,661 |
| Ross Moat | Executive Vice President and Chief Operating Officer | $3,638,001 |
| John Paolini | Executive Vice President and Chief Medical Officer | $3,570,655 |
| Eben Tessari · this page | Executive Vice President and Chief Strategy Officer | $3,566,231 |
| Mark Ragosa | Executive Vice President and Chief Financial Officer | $3,283,055 |
The full Kiniksa Pharmaceuticals International compensation record
free company briefThis page is one person within Kiniksa Pharmaceuticals International's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Kiniksa Pharmaceuticals International's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kiniksa Pharmaceuticals International's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat